The mechanisms that regulate the expression of the NKG2D and DNAM-1 activating ligands are only partially known, but it is now widely established that their expression is finely regulated at transcriptional, post-transcriptional and post-translational level, and involve numerous stress pathways depending on the type of ligand, stressor, and cell context. We show that treatment of Multiple Myeloma (MM) cells with sub-lethal doses of Vincristine (VCR), an anticancer drug that inhibits the assembly of microtubules, stimulates the expression of NKG2D and DNAM-1 activating ligands, rendering these cells more susceptible to NK cell-mediated killing. Herein, we focused our attention on the identification of the signaling pathways leading to de novo surface expression of ULBP-1, and to MICA and PVR upregulation on VCR-treated MM cells, both at protein and mRNA levels. We found that p38MAPK differentially regulates drug-dependent ligand upregulation at transcriptional and post-transcriptional level. More specifically, we observed that ULBP-1 expression is attributable to both increased transcriptional activity mediated by ATM-dependent p53 activation, and enhanced mRNA stability; while the p38-activated E2F1 transcription factor regulates MICA and PVR mRNA expression. All together, our findings reveal a previously unrecognized activity of VCR as anticancer agent, and indicate that in addition to its established ability to arrest cell growth, VCR can also modulate the expression of NKG2D and DNAM-1 activating ligand on tumor cells and thus promoting NK cell-mediated immunosurveillance.

p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells / Soriani, Alessandra; Borrelli, Cristiana; Ricci, Biancamaria; Molfetta, Rosa; Zingoni, Alessandra; Fionda, Cinzia; Carnevale, Silvia; Abruzzese, MARIA PIA; Petrucci, MARIA TERESA; Ricciardi, Maria Rosaria; LA REGINA, Giuseppe; Cesare, Erica Di; Lavia, Patrizia; Silvestri, Romano; Paolini, Rossella; Cippitelli, Marco; Santoni, Angela. - In: ONCOIMMUNOLOGY. - ISSN 2162-402X. - ELETTRONICO. - 6:1(2017), pp. e1264564-e1264564. [10.1080/2162402X.2016.1264564]

p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells

SORIANI, Alessandra
;
BORRELLI, CRISTIANA
;
MOLFETTA, Rosa;ZINGONI, Alessandra;FIONDA, Cinzia;ABRUZZESE, MARIA PIA;PETRUCCI, MARIA TERESA;RICCIARDI, Maria Rosaria;LA REGINA, GIUSEPPE;SILVESTRI, Romano;PAOLINI, Rossella;CIPPITELLI, Marco;SANTONI, Angela
2017

Abstract

The mechanisms that regulate the expression of the NKG2D and DNAM-1 activating ligands are only partially known, but it is now widely established that their expression is finely regulated at transcriptional, post-transcriptional and post-translational level, and involve numerous stress pathways depending on the type of ligand, stressor, and cell context. We show that treatment of Multiple Myeloma (MM) cells with sub-lethal doses of Vincristine (VCR), an anticancer drug that inhibits the assembly of microtubules, stimulates the expression of NKG2D and DNAM-1 activating ligands, rendering these cells more susceptible to NK cell-mediated killing. Herein, we focused our attention on the identification of the signaling pathways leading to de novo surface expression of ULBP-1, and to MICA and PVR upregulation on VCR-treated MM cells, both at protein and mRNA levels. We found that p38MAPK differentially regulates drug-dependent ligand upregulation at transcriptional and post-transcriptional level. More specifically, we observed that ULBP-1 expression is attributable to both increased transcriptional activity mediated by ATM-dependent p53 activation, and enhanced mRNA stability; while the p38-activated E2F1 transcription factor regulates MICA and PVR mRNA expression. All together, our findings reveal a previously unrecognized activity of VCR as anticancer agent, and indicate that in addition to its established ability to arrest cell growth, VCR can also modulate the expression of NKG2D and DNAM-1 activating ligand on tumor cells and thus promoting NK cell-mediated immunosurveillance.
2017
activating ligands; chemoimmunotherapy; multiple myeloma; nk cells
01 Pubblicazione su rivista::01a Articolo in rivista
p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells / Soriani, Alessandra; Borrelli, Cristiana; Ricci, Biancamaria; Molfetta, Rosa; Zingoni, Alessandra; Fionda, Cinzia; Carnevale, Silvia; Abruzzese, MARIA PIA; Petrucci, MARIA TERESA; Ricciardi, Maria Rosaria; LA REGINA, Giuseppe; Cesare, Erica Di; Lavia, Patrizia; Silvestri, Romano; Paolini, Rossella; Cippitelli, Marco; Santoni, Angela. - In: ONCOIMMUNOLOGY. - ISSN 2162-402X. - ELETTRONICO. - 6:1(2017), pp. e1264564-e1264564. [10.1080/2162402X.2016.1264564]
File allegati a questo prodotto
File Dimensione Formato  
Soriani_p38_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 989.63 kB
Formato Adobe PDF
989.63 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/902826
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 24
social impact